Patents by Inventor Troy D. Randall
Troy D. Randall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150064192Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: November 14, 2014Publication date: March 5, 2015Inventors: DANIEL M. GORMAN, TROY D. RANDALL, ALBERT ZLOTNIK
-
Publication number: 20130324483Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: August 9, 2013Publication date: December 5, 2013Applicant: Merck Sharp & Dohme Corp.Inventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik
-
Publication number: 20120094937Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: December 20, 2011Publication date: April 19, 2012Applicant: Schering CorporationInventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik
-
Patent number: 8084035Abstract: The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni.Type: GrantFiled: February 9, 2010Date of Patent: December 27, 2011Assignee: Trudeau Institute, Inc.Inventors: Frances E. Lund, Troy D. Randall, Santiago Partida-Sanchez
-
Publication number: 20100297148Abstract: The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni.Type: ApplicationFiled: February 9, 2010Publication date: November 25, 2010Inventors: Frances E. Lund, Troy D. Randall, Santiago Partida-Sanchez
-
Patent number: 7695933Abstract: The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni.Type: GrantFiled: February 15, 2005Date of Patent: April 13, 2010Assignee: Trudeau Institute, Inc.Inventors: Frances E. Lund, Troy D. Randall, Santiago Partida-Sanchez
-
Patent number: 7025962Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: April 10, 2000Date of Patent: April 11, 2006Assignee: Schering CorporationInventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik
-
Patent number: 6955884Abstract: The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. The invention is based on the discovery that CD38 ADP-ribosyl cyclase activity is required for chemotaxis. Furthermore, the invention relates to methods for identifying compounds that modulate the enzyme activity of the S. mansoni CD38 homologue and using those compounds in the treatment of pathologic disorders caused by helminth infection.Type: GrantFiled: October 17, 2001Date of Patent: October 18, 2005Assignee: Trudeau Institute, Inc.Inventors: Frances E. Lund, Troy D. Randall, Santiago Partida-Sánchez
-
Publication number: 20020127646Abstract: The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such compounds in the treatment of disorders involving CD38 modulated cell migration. The invention is based on the discovery that CD38 ADP-ribosyl cyclase activity is required for chemotaxis. Furthermore, the invention relates to methods for identifying compounds that modulate the enzyme activity of the S. mansoni CD38 homologue and using those compounds in the treatment of pathologic disorders caused by helminth infection.Type: ApplicationFiled: October 17, 2001Publication date: September 12, 2002Inventors: Frances E. Lund, Troy D. Randall, Santiago Partida-Sanchez
-
Patent number: 6111090Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: August 14, 1997Date of Patent: August 29, 2000Assignee: Schering CorporationInventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik